Efficacy and safety of rivaroxaban in the prevention of deep vein thrombosis in patients with hip arthroplasty

VernacularTitle:利伐沙班预防老年髋关节置换术后下肢静脉血栓的临床疗效及安全性研究
Author: Jian LI ¹ ; Yun-Ji CENG ; Jin-Tu XIE ; Ru-Jie ZHUANG
Author Information

1. 杭州师范大学附属医院骨科
Keywords: rivaroxaban; hip arthroplasty; deep vein thrombosis; low molecular heparin
From: The Chinese Journal of Clinical Pharmacology 2014;(9):762-764
CountryChina
Language:Chinese
Abstract: Objective To investigate the efficacy and safety of rivaroxa-ban in the prevention of deep vein thrombosis in patients with hip arthro-plasty.Methods Ninety-eight patients with hip arthroplasty were re-cruited in our hospital.The included 98 cases were randomized divided into rivaroxaban group ( n=46 ) with rivaroxaban 10 mg · d -1 orally with 5-week and low molecular heparin ( LMH) group with LMH 4100 U with 2-week.The risk of deep vein thrombosis between the two groups was recorded within the flowing 6 months.Results With a follow-up peri-od of 6 months, the incidence of deep vein thrombosis were 2.3%(1/44) and 14.6%(7/58) in the rivaroxaban group and LMH group re-spectively , which indicated the incidence was much lower in rivaroxaban group ( P<0.05 ).But the platelet count , coagulation function , drainage volume and subcutaneous ecchymosis were not different between the two groups ( P>0.05 ).Conclusion Rivaroxaban can significant decrease the risk of deep vein thrombosis in patients with hip arthroplasty without increasing the side effects.